Previous Article | Next Article 
Journal of Virology, April 2000, p. 3781-3792, Vol. 74, No. 8
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The IRF-3 Transcription Factor Mediates Sendai
Virus-Induced Apoptosis
Christophe
Heylbroeck,1,2
Siddharth
Balachandran,3
Marc J.
Servant,1,4
Carmela
DeLuca,1,4
Glen N.
Barber,3
Rongtuan
Lin,1,2,3 and
John
Hiscott1,2,3,*
Terry Fox Molecular Oncology Group, Lady
Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish
General Hospital,1 and Departments of
Microbiology and Immunology2 and
Medicine,4 McGill University, Montreal,
Quebec, Canada H3T 1E2, and Sylvester Comprehensive Cancer
Center, Department of Microbiology and Immunology, University of Miami,
Miami, Florida 331363
Received 8 October 1999/Accepted 21 January 2000
 |
ABSTRACT |
Virus infection of target cells can result in different biological
outcomes: lytic infection, cellular transformation, or cell death by
apoptosis. Cells respond to virus infection by the activation of
specific transcription factors involved in cytokine gene regulation and
cell growth control. The ubiquitously expressed interferon regulatory
factor 3 (IRF-3) transcription factor is directly activated following
virus infection through posttranslational modification. Phosphorylation
of specific C-terminal serine residues results in IRF-3 dimerization,
nuclear translocation, and activation of DNA-binding and
transactivation potential. Once activated, IRF-3 transcriptionally up
regulates alpha/beta interferon genes, the chemokine RANTES, and
potentially other genes that inhibit viral infection. We previously
generated constitutively active [IRF-3(5D)] and dominant negative
(IRF-3
N) forms of IRF-3 that control target gene expression. In an
effort to characterize the growth regulatory properties of IRF-3, we
observed that IRF-3 is a mediator of paramyxovirus-induced apoptosis.
Expression of the constitutively active form of IRF-3 is toxic,
preventing the establishment of stably transfected cells. By using a
tetracycline-inducible system, we show that induction of IRF-3(5D)
alone is sufficient to induce apoptosis in human embryonic kidney 293 and human Jurkat T cells as measured by DNA laddering, terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling
assay, and analysis of DNA content by flow cytometry. Wild-type IRF-3
expression augments paramyxovirus-induced apoptosis, while expression
of IRF-3
N blocks virus-induced apoptosis. In addition, we
demonstrate an important role of caspases 8, 9, and 3 in IRF-3-induced
apoptosis. These results suggest that IRF-3, in addition to potently
activating cytokine genes, regulates apoptotic signalling following
virus infection.
 |
INTRODUCTION |
Apoptosis, or programmed cell death,
plays a critical role in maintaining the homeostasis of multicellular
organisms by specifically removing damaged, spent, or misplaced cells
(22). Apoptosis can be induced rapidly through death
receptor engagement (3, 41) or in response to a wide variety
of cellular stresses, including DNA damage, withdrawal of growth
factors, and pathogen assault (51). Following an apoptotic
stimulus, cells initiate signalling pathways that lead to the
activation of cellular death proteases termed caspases and culminate
with the degradation of the cellular machinery, giving rise to the
classical apoptotic morphology (11, 50, 51).
Viral replication can induce cells to undergo apoptosis. Cells commit
suicide as a host defense mechanism, limiting the spread of progeny
virus and preventing oncogenic transformation by oncogenic viruses
(42). Induction of apoptosis, however, can also benefit the
virus: apoptosis of virus-infected cells can lead to increased viral
dissemination while evading immune recognition. Many viruses have
evolved strategies to suppress or delay the induction of apoptosis,
underscoring the importance of this mechanism in immune control.
Epstein-Barr virus encodes a functional homologue of the anti-apoptotic
protein Bcl-2 (18), and via its latent membrane protein-1,
it up regulates the expression of the anti-apoptotic gene
bcl-2 and activates the NF-
B signalling pathway (19,
44), both of which have been implicated in cell survival (1,
6, 41). Other viruses, including human papillomavirus and
adenovirus, express proteins which inactivate p53, thereby ablating
induction of p53-dependent apoptosis (48). Several other
viruses have adopted a common strategy: baculovirus protein p53 and
poxvirus CrmA inhibit the activation of caspases (10, 30).
Kaposi sarcoma-associated human herpesvirus 8 also specifically encodes
an inhibitor of caspase 8, thereby preventing T cells from eliminating
infected cells by death receptor induction (49).
One of the immediate cellular responses to viral infection involves the
secretion of interferons (IFNs) (52). In addition to their
antiviral and immunomodulatory properties, IFNs have recently been
shown to be important regulators of virus-induced apoptosis. IFNs
elicit an antiviral state in uninfected cells through the
transcriptional activation of anti-viral proteins while inducing
apoptosis in virus-infected cells (47). IFNs are upregulated
through the coordinate activation of transcriptional regulatory
proteins NF-
B and IFN regulatory factors (IRFs) (20). Virus-induced posttranslational phosphorylation of IRF-3 is thought to
stimulate beta IFN (IFN-
) production (21). Secreted
IFN-
(and IFN-
4 in murine cells) then acts through the JAK-STAT
pathway to stimulate the production of a distinct member of the IRF
family
IRF-7
which in turn contributes to the transcriptional
induction of other IFN-
genes (5, 29, 39).
The IRF family of transcription factors includes nine mammalian
members; IRF-1 to -7, ICSBP (now designated IRF-8), and p48 (designated
IRF-9), as well as several viral homologs (32). IRF-3 is a
55-kDa protein that is expressed constitutively in all tissues
(4). In response to virus infection or treatment with
double-stranded (ds) RNA, IRF-3 is phosphorylated on specific C-terminal serine and threonine residues (26, 54, 56). This posttranslational modification leads to IRF-3 dimerization and translocation into the nucleus and the transcriptional activation of
target genes (26, 27, 53, 54, 56). IRF-3 requires the
coactivator CREB-binding protein (CBP)-p300 to mediate transcriptional activation and is important for regulating viral induction of the
chemokine RANTES as well as IFN genes (25, 26, 37, 54, 56).
Substitution of these serine and threonine residues in the amino acid
396 to 405 region of IRF-3 with aspartic acids creates a constitutively
active form of IRF-3 that is able to stimulate transcription in the
absence of virus induction (26).
In this study, we demonstrate that IRF-3 is an essential mediator of
paramyxovirus-induced apoptosis. Initial experiments demonstrated that
expression of the constitutively active form of IRF-3 was toxic in both
Jurkat T cells and human embryonic kidney 293 cells, thus preventing
the establishment of stably transfected cells. To circumvent this
effect, a tetracycline (TET)-inducible system was used to demonstrate
that induced expression of the constitutively active form of IRF-3 was
sufficient to produce apoptosis in both Jurkat and 293 cells. Wild-type
IRF-3 expression augmented paramyxovirus-induced apoptosis in both cell
types, whereas expression of a truncated dominant negative form of
IRF-3 blocked virus-induced apoptosis. These results suggest that
IRF-3, in addition to potently activating cytokine genes, functions to regulate apoptotic signalling in response to virus infection.
 |
MATERIALS AND METHODS |
Cell culture and virus infection.
Human embryonic kidney 293 or Jurkat T cells were grown in minimal essential medium alpha (
MEM)
(293) or RPMI 1640 (Jurkat) medium (GIBCO-BRL) supplemented with 10%
fetal bovine serum (FBS), glutamine, and antibiotics. In experiments
where control and IRF-3-expressing cells were virus infected, Sendai
virus (80 hemagglutinating units [HAU]/ml) (a kind gift from I. Julkunen) was added to the cells for 1 h in serum-free media.
After incubation, cells were washed and placed in growth media
containing 10% FBS. For the doxycycline (DOX)-inducible cell lines,
cells were pretreated with 1 µg of DOX per ml for 12 h (Jurkat T
cells) or for 24 h (293 cells) and were maintained with DOX for
the duration of the infection.
Plasmid constructions and mutagenesis.
The wild-type and
mutated forms of IRF-3-expressing plasmids were described previously
(26).
Generation of IRF-3 and IRF-3(5D) cell lines.
Plasmid
CMVt-rtTA (33) was introduced into human
embryonic kidney 293 cells by the calcium phosphate method and into
human Jurkat T cells by electroporation. Forty-eight hours after
transfection, cells were grown in
MEM (GIBCO-BRL) (293 cells) or
RPMI 1640 (GIBCO-BRL) (Jurkat cells) medium containing 10%
heat-inactivated FBS, glutamine, antibiotics, and 2.5 ng of puromycin
(Sigma) per µl. Resistant cells carrying the CMVt-rtTA
plasmid (rtTA-293 cells or rtTA-Jurkat cells) were then transfected
with the CMVt-IRF-3 and CMVt-IRF-3(5D)
plasmids. Cells were placed in selective media (growth media with 2.5 ng of puromycin per µl and 400 µg of G418 per ml) 48 h after
transfection and were monitored for approximately 2 weeks. For
generation of IRF-3
N cells, IRF-3
N/pEGFPC1 was introduced into
293 cells by the calcium phosphate method, and cells were selected with
G418 as described above.
Colony formation assay.
293 cells were transfected with 10 µg each of control pEGFPC1 vector, pEGFPC1-IRF-3, and
pEGFPC1-IRF-3(5D). Thirty six hours after transfection, cells were
placed in selection media containing 400 µg of G418 (Life
Technologies, Inc.) per ml. Two weeks later, cells were fixed with
ice-cold methanol and were Giemsa stained (Life Technologies, Inc.).
Expression of the green fluorescent protein (GFP) fusion proteins was
monitored by fluorescence microscopy.
Western blot analysis.
To screen and characterize the
kinetics of IRF-3 and IRF-3(5D) induction, the expressing cells were
cultured in the presence of 1 µg of DOX per ml for various times.
Cells were washed with phosphate-buffered saline (PBS) and were lysed
in 10 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EDTA, 1 mM
dithiothreitol, 0.5% Nonidet P-40, 0.5 mM phenylmethysulfonyl
fluoride, 5 µg of leupeptin per ml, 5 µg of pepstatin per ml, and 5 µg of aprotinin per ml. Equivalent amounts of whole-cell extract (20 to 40 µg) were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) in a 10% (IRF-3) or 15% (CPP-32)
polyacrylamide gel. After electrophoresis, the proteins were
transferred to Hybond transfer membrane (Amersham) in a buffer
containing 30 mM Tris, 200 mM glycine, and 20% methanol for 1 h.
The membrane was blocked by incubation in PBS containing 5% milk for
1 h and was then probed with IRF-3 or CPP-32 antibody (kind gifts
from P. Pitha and P. R. Sékaly, respectively) in 5%
milk-PBS (dilution 1:3,000) at 4°C overnight. After four 10-min washes with PBS, membranes were reacted with a peroxidase-conjugated secondary goat anti-rabbit antibody (Amersham) at a dilution of 1:2,500. The reaction was then visualized with the enhanced
chemiluminescence detection system (ECL) as recommended by the
manufacturer (Amersham).
Flow cytometry.
For fluorescence-activated cell sorter
(FACS) analysis of Jurkat T cells, 5 × 106 cells were
washed in PBS and were fixed in 70% ethanol in PBS for 1 h. Cells
were then washed three times with PBS and were stained at 4°C
overnight in 0.5 mM Tris (pH 8.0), 1.5 mM spermine tetrahydrochloride,
35 µg of RNase A per ml, and 50 µg of propidium iodide per ml.
Cells were analyzed by FACStar using the Consort 30 software (Becton Dickinson).
DNA fragmentation.
Following treatments, ~2 × 106 cells were pelleted, were washed with PBS, were
resuspended in 250 µl of lysis buffer (20 mM Tris HCl [pH 7.5], 10 mM borate, 0.25% Nonidet P-40, 0.1 mg of RNase per ml), and were
incubated for 1 h at 37°C. Proteinase K was added to a final
concentration of 1 mg/ml, and extracts were incubated for an additional
1 h. Samples were separated on a 1.8% agarose gel containing 0.5 µg of ethidium bromide per ml and were visualized by UV illumination.
TUNEL analysis.
Apoptosis was quantified by using an in situ
cell death detection kit (Boehringer Mannheim). Approximately
106 cells were centrifuged, washed once with PBS, and
resuspended in 20 µl of PBS (on a multichamber slide) or in 100 µl
of PBS (FACS analysis). For the multichamber slide, cells were plated, air dried, and fixed with 4% paraformaldehyde for 30 min at room temperature. Slides were rinsed twice with PBS and were incubated for 2 min at 4°C in permeabilization solution (0.1% Triton X-100 and 0.1%
sodium citrate), were rinsed with PBS, and were incubated with
fluorescein-labelled terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) reaction mixture for 1 h at
37°C in a humid, darkened chamber. Slides were again rinsed with PBS,
were incubated with the DNA dye Hoechst 33342 (0.4 ng/ml) to visualize
all nuclei, were washed with PBS, and were embedded in mounting
solution (10 mM Tris HCL [pH 8.8] and 0.1 M propyl gallate in
glycerol). Samples were analyzed by fluorescence microscopy, and the
percentage of apoptotic cells was determined by counting a minimum of
350 nuclei (blue filter) and the corresponding TUNEL-positive cells
(green filter). For FACS analysis, a similar protocol was used, except
that U-bottomed 96-well plates were used instead of multichamber
slides. Cells were analyzed by FACStar by using the Consort 30 software
(Becton Dickinson).
MTT assay.
293 cells were plated at a concentration of 1,000 cells/well in a 96-well plate. After 24 h, cells were treated with
different inducers and were subsequently analyzed by metallothionin
(MTT) assay. Briefly, the medium was replaced by fresh medium
containing 10 mM of PIPES
[4-(2-hydroxyethyl)-1-piperamine-ethanesulfonic acid] buffer (pH 7.4)
and 0.5 mg of MTT
[3-(4,5-dimethylthiazol-2-
1)-2,5-diphenyltetrazolium bromide] per
ml. The plates were wrapped in aluminum foil and were further incubated
for 4 h at 37°C. The medium and MTT were removed, and the
crystals that had formed in each well were dissolved with 225 µl of a
solution containing 200 µl of dimethylsulfoxide and 25 µl of
glycine buffer (0.1 M glycine, 0.1 M NaCl [pH 10.5]). Absorbance was
read by using an enzyme-linked immunosorbent assay plate reader (model
450; Bio-Rad Laboratories, Watford, England), interfaced to a Macintosh computer.
RPA.
For ribonuclease protection assay (RPA), total RNA
isolated from 293 or Jurkat T cell pellets was prepared using the
RNAeasy kit (Qiagen). Total RNA (5 µg) was subjected to RPA by using
the hCK-3 chemokine template of the RiboQuant multi-probe RPA kit, following the manufacturer's instructions (Pharmingen, San Diego, Calif.).
Caspase assay.
For quantifying caspase activity. Jurkat T
cells (5 × 106 cells) expressing IRF-3(5D) were
washed in cold PBS, lyzed, and incubated with fluorogenic substrates
for caspase 8 (IETD-AFC; Clontech) or caspase 9 (LEHD-AFC; Enzyme
Systems Products) as described in the Apoalert FLICE/Caspase-8 assay
kit (Clontech). This kit can also be modified to measure caspase 9 activity (Clontech). AFC fluorescence emission was detected at 505 nm,
following excitation at 400 nm with a fluorescence spectrophotometer.
Caspase inhibitor assay.
Noninduced, DOX-induced, and/or
Jurkat T cells infected for various times with Sendai virus were
aliquoted into the wells of a 96-well plate at a concentration of
50,000 cells/well/100 µl of medium in the presence or absence of a
solution containing 200 µM zVAD, zIETH, zLEHD, 4 µg of APO-1-3 per
ml (Kamiya Biomedical), and 50 µM Etoposide (Sigma). At 24, 48, or
72 h after treatment, cell viability was determined by Trypan blue exclusion.
 |
RESULTS |
Generation of TET-inducible cell lines.
In order to identify
genes that may be regulated by the IRF-3 transcription factor, we
sought to generate stable cell lines expressing different forms of
IRF-3. The pEGFPC1 control vector and vectors encoding GFP-wild-type
IRF-3 (wtIRF-3) and a constitutively active form of IRF-3,
GFP-IRF-3(5D), were transfected in 293 human embryonic kidney cells.
After 2 weeks of selection in G418-containing medium, an equal number
of clones (250 to 300 clones per 100-mm-diameter plate) expressing the
control vector or wtIRF-3 were obtained (Fig. 1A and
B). In contrast, only a few clones (25 to
30 clones per 100-mm-diameter plate) were obtained from cells
transfected with IRF-3(5D), revealing a possible toxic effect of the
transgene (Fig. 1C). Moreover, clones isolated from the
IRF-3(5D)-transfected cells did not express the GFP fusion protein
(data not shown). To circumvent this effect, 293 and Jurkat cells that
inducibly expressed wtIRF-3 and IRF-3(5D) under the control of a
TET-inducible promoter were generated, as previously described
(25). Polyclonal populations of 293 and Jurkat cells were
screened for DOX-inducible expression of the transgene by immunoblot
analysis. wtIRF-3 and IRF-3(5D) were inducible following DOX induction,
with high levels of IRF-3 evident at 18 h in rtTA-293 wtIRF-3
cells (Fig. 2A, lane 6), at 8 h in
rtTA-293 IRF-3(5D) cells (Fig. 2B, lane 4) and rtTA-Jurkat wtIRF-3
cells (Fig. 2C, lane 4), and as early as at 4 h in rtTA-Jurkat IRF-3(5D) cells (Fig. 2D, lane 3). The IRF-3(5D) protein migrated more
slowly on SDS-PAGE than endogenous IRF-3 protein, at a position similar
to phosphorylated IRF-3 (25). In contrast to cell lines transfected with wtIRF-3, cell lines transfected with IRF-3(5D) did not
exhibit any expression of the transgene in the absence of DOX induction
(Fig. 2B and D, lanes 2), further suggesting that leakiness of the
IRF-3(5D) transgene under unstimulated conditions prevented the
selection of stable cell clones.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 1.
Constitutively active IRF-3 is toxic to cells. 293 cells
were transfected with 10 µg of control pEGFPC1 vector (A),
pEGFPC1-wtIRF-3 (B), or pEGFPC1-IRF-3(5D) (C). Beginning 36 h
after transfection, cells were selected in media containing G418 (400 µg/ml); after 2 weeks of selection, cells were fixed in the plate
with ice-cold methanol and were stained with Giemsa. Expression of the
GFP fusion proteins was monitored by fluorescence microscopy.
|
|

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 2.
Inducible expression of IRF-3 and IRF-3(5D). Whole-cell
extracts (20 µg) were prepared from rtTA-293 (A and B) and
rtTA-Jurkat (C and D) cells. rtTA-293 wtIRF-3 (A), rtTA-293 IRF-3(5D)
(B), rtTA-Jurkat wtIRF-3 (C), and rtTA-Jurkat IRF-3(5D) (D) cells were
induced with DOX (1 µg/ml) for 0 to 48 h and were analyzed for
IRF-3 expression by immunoblot analysis. IRF-3(5D) protein migrated
more slowly than endogenous IRF-3 protein on SDS-PAGE at a position
similar to phosphorylated IRF-3 protein.
|
|
Constitutively active IRF-3 induces apoptosis.
To study the
effect of wtIRF-3 and IRF-3(5D) on cell-growth regulation, IRF-3 was
expressed following the addition of DOX to the rtTA-293 wtIRF-3- and
rtTA-293 IRF-3(5D)-inducible cell lines. The addition of DOX resulted
in cell death in IRF-3(5D)-expressing cells beginning at 48 h but
did not cause cell death in wtIRF-3-expressing cells. wtIRF-3- and
IRF-3(5D)-expressing 293 cells were next assayed for apoptosis by the
TUNEL method (Fig. 3A)
and by DNA fragmentation (Fig. 3B).
DOX-induced control rtTA-293 and rtTA-293 wtIRF-3 cells were TUNEL
negative and showed no spontaneous DNA fragmentation (Fig. 3B), while
rtTA-293 IRF-3(5D) cells were TUNEL positive (approximately 25%) (Fig.
3A) and exhibited DNA fragmentation starting 2 days after DOX induction
with peak levels on days 4 and 5 (Fig. 3B). IRF-3(5D)-induced apoptosis
was also examined in rtTA-IRF-3-expressing Jurkat T cells by monitoring
for TUNEL-positive staining (Fig. 3C) and DNA content by propidium
iodide staining and flow cytometry analysis (Fig. 3D). DOX induction of
the IRF-3(5D) resulted in 33% apoptosis by 48 h, and the number
of detectable apoptotic cells had increased to 55% by 72 h.
Addition of DOX to rtTA-Jurkat control cells and wtIRF-3-expressing
Jurkat cells did not increase the low level of apoptosis in these cells
(Fig. 3D).



View larger version (333730K):
[in this window]
[in a new window]
|
FIG. 3.
Constitutively active IRF-3 induces apoptosis. TUNEL
staining of IRF-3(5D)-expressing 293 (A) and Jurkat cells (C). rtTA-293
IRF-3(5D) and rtTA-Jurkat IRF-3(5D) cells were left untreated or
induced with DOX for 48 (293) or 72 h (Jurkat). Cells were then
stained by the TUNEL method (green filter) and with Hoechst dye to
visualize all nuclei (blue filter) as described in Materials and
Methods. (B) Kinetics of DNA fragmentation in 293 IRF-3(5D)-expressing
cells. Plates of rtTA-, wtIRF-3-, and IRF-3(5D)-expressing 293 cells
were induced with DOX (1 µg/ml) for 0 to 5 days. DNA was isolated
from each sample and was analyzed by agarose gel electrophoresis as
described in Materials and Methods. (D) Kinetics of IRF-3(5D)-induced
apoptosis in Jurkat T cells. wtIRF-3- and IRF-3(5D)-expressing Jurkat T
cells were induced with DOX (1 µg/ml) for 0 to 72 h as
indicated. Cells (5 × 106) were fixed and stained
with propidium iodide. Cellular DNA content was analyzed by flow
cytometry.
|
|
IRF-3 mediates virus-induced apoptosis.
Since IRF-3 is
directly activated following virus infection, we sought to examine
whether IRF-3 was involved in virus-induced apoptosis. Control and
Jurkat cells overexpressing wtIRF-3 or IRF-3(5D) were infected with
Sendai virus and were subsequently stained with propidium iodide for
FACS analysis (Fig. 4). Sendai virus
infection of rtTA-Jurkat cells resulted in approximately 15% apoptosis
(Fig. 4B), while overexpression of wtIRF-3 increased the number of
apoptotic cells to 30% (Fig. 4D). The response to virus infection in
uninduced IRF-3(5D)-expressing Jurkat cells was similar to control
cells (Fig. 4F) while overexpression of IRF-3(5D)-induced apoptosis in
60% of the population (Fig. 4G); the combination of virus infection
and overexpression of IRF-3(5D) resulted in almost 66% cell death
(Fig. 4H).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
IRF-3 potentiates virus-induced apoptosis. rtTA-Jurkat
(A and B), rtTA-Jurkat wtIRF-3 (C and D), and rtTA-Jurkat IRF-3(5D) (E
to H) were cultured in the presence (A to D, G, and H) or absence of
DOX (1 µg/ml) (E and F). After 12 h, cells were either left
untreated (A, C, E, and G) or were infected with Sendai virus (80 HAU/ml) for 72 h (B, D, F, and H). Cells (5 × 106) were fixed and stained with propidium iodide. Cellular
DNA content was analyzed by flow cytometry.
|
|
Next, a dominant negative mutant of IRF-3 lacking most of the DNA
binding domain (IRF-3
N) was used to examine the involvement of
IRF-3 in virus-mediated apoptosis. This dominant negative mutant of
IRF-3 has been shown to block downstream target gene activation (25). 293 cells overexpressing wtIRF-3 or IRF-3
N were
infected with Sendai virus and were analyzed for virus induced
apoptosis by TUNEL analysis. Virus infection of control 293 cells
resulted in 25 to 30% apoptosis by 72 h after infection, whereas
the level of apoptosis in wtIRF-3-expressing cells was more pronounced. Nonstimulated rtTA-293 wtIRF-3 cells showed approximately the same
amount of apoptosis as control 293 cells (25% at 72 h
postinfection), whereas the same cells exhibited a threefold increase
in TUNEL positive cells following DOX induction. By 24 h
postinfection, 20% of the cells were apoptotic; the level of apoptosis
increased to approximately 60% after 48 h, and by 72 h after
virus infection about 75% of the cell population was apoptotic (Fig.
5). The essential role of IRF-3 in
mediating virus-induced apoptosis was highlighted by the observation
that expression of the dominant negative form of IRF-3 blocked the
induction of apoptosis by viral infection; less than 15% of the cells
were apoptotic at 72 h postinfection (Fig. 5).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
Inhibition of virus-induced apoptosis. Control 293 and
293 IRF-3 N-expressing cells were left untreated or were infected
with Sendai virus (80 HAU/ml) for 24, 48, and 72 h. rtTA-293
wtIRF-3 were cultured in the presence or absence of DOX (1 µg/ml) as
indicated. After 24 h, cells were either left untreated or were
infected with Sendai virus as described above. The number of apoptotic
cells was determined by TUNEL staining as described in Materials and
Methods.
|
|
IFN release is not implicated in IRF-3-induced apoptosis.
Since constitutively active IRF-3 has been shown to be a strong
activator of interferon and cytokine gene expression (25, 26), we investigated the possibility that IRF-3 may stimulate IFN
production which in turn may induce apoptosis, since IFN has been shown
to induce apoptosis in virus-infected cells (47). IFN
treatment alone did not induce apoptosis in Jurkat cells. As shown
in Fig. 6A
and B, the addition of a neutralizing
antibody against IFN-
did not protect 293 or Jurkat cells from
Sendai virus-induced apoptosis, as measured by MTT or TUNEL assays,
respectively. The MTT assay, which reflects mitochondrial activity, was
used as a marker of cell death in Fig. 6A. Moreover, cotreatment of both cell types with Sendai virus and IFN-
did not increase the level of cell death beyond that induced by virus alone (Fig. 6A and B).
Expression of IRF-3
N abrogated 50% of Sendai virus-induced apoptosis (Fig. 6A); this data was similar to that by TUNEL assay presented in Fig. 5. The efficacy of the neutralizing antibody was
demonstrated by the inhibition of IFN-
stimulation of an IFN-stimulated response element (ISRE)-containing reporter gene construct (ISG-15-CAT) in transient transfections (data not shown). RNase protection analysis further demonstrated that while Sendai virus
infection induced IFN-
mRNA in 293 and Jurkat cells, IRF-3(5D) overexpression alone was not sufficient to induce IFN-
mRNA in either cell type (Fig. 6C). Similarly, no IFN-
mRNA was detected (Fig. 6C). Finally, Jurkat T cells grown in the conditioned media derived from rtTA-Jurkat or rtTA-Jurkat IRF-3(5D) cells induced with
DOX for 72 h did not undergo apoptosis (data not shown). Altogether, these data indicated that IFN production was not involved in the induction of apoptosis by IRF-3.


View larger version (1291K):
[in this window]
[in a new window]
|
FIG. 6.
IFN release is not implicated in IRF-3-induced
apoptosis. (A) Control 293 and 293 IRF-3 N-expressing cells were
left untreated or were infected with Sendai virus (80 HAU/ml) for 24, 48, and 72 h in the presence or absence of IFN- (400 IU/ml) or
neutralizing antibody for alpha/beta interferon (1/100) (Sigma) as
indicated. Viability was measured by using an MTT assay as described in
Materials and Methods. Symbols: , 293; , 293 plus IFN- ; ,
293 plus anti-IFN- ; , 293 IRF-3 N. (B) TUNEL staining of
Jurkat cells. The rtTA-Jurkat cells were either left untreated, were
infected with Sendai virus (80 HAU/ml), or were treated with IFN-
(400 IU/ml) for 72 h; anti-IFN- antibody was added with Sendai
virus. The number of apoptotic cells was determined by TUNEL as
described in Materials and Methods. (C) RPA of IFN- and IFN- mRNA
production. The rtTA-, wtIRF-3-, and IRF-3(5D)-expressing 293 and
Jurkat cells were cultured in the presence or absence of DOX, as
indicated, for 24 h. Cells were then either left untreated or were
infected with Sendai virus for 72 h. Total RNA was isolated from
each sample and was analyzed by RNase protection analysis by using the
human CK-3 RPA kit (Pharmingen), according to manufacturer's
instructions.
|
|
Activation of CPP-32/caspase 3.
To examine which members of
the caspase family were involved in these apoptotic processes,
CPP-32/caspase 3 activation was monitored by immunoblot analysis (Fig.
7). Following an apoptotic stimulus,
CPP-32 proenzyme is processed into two subunits, the active subunit
(p17) and a smaller subunit (p12) (35). Whereas only low
levels of the active p17 subunit of caspase 3 could be detected in
control 293 and rtTA-Jurkat cells after Sendai virus infection (Fig. 7A
and B, lanes 1 to 4), both Jurkat and 293 cell lines overexpressing
wtIRF-3 showed a progressive decrease in the amount of full-length
caspase 3 and an increase in the levels of active p17 caspase 3 subunit
after virus infection (Fig. 7A and B, lanes 5 to 8). Induction of the
constitutively active IRF-3(5D) with DOX had a similar effect: caspase
3 was activated 48 h after DOX induction (Fig. 7A and B, lanes
11), in agreement with the kinetics of induction of apoptosis.

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 7.
CPP-32 activation in virus-infected and
IRF-3(5D)-expressing cells. (A) Whole-cell extracts from 293 and
DOX-induced rtTA-wtIRF-3-, and IRF-3(5D)-expressing 293 cells infected
with Sendai virus (80 HAU/ml) or treated with DOX for the times
indicated were subjected to SDS-PAGE and were transferred to
nitrocellulose membrane. (B) Whole-cell extracts from untreated or
DOX-induced rtTA-, wtIRF-3-, or IRF-3(5D)-expressing Jurkat cells
infected with Sendai virus (80 HAU/ml) or induced with DOX for the
times indicated were subjected to SDS-PAGE and were transferred to
nitrocellulose membrane. CPP-32 and its cleavage products were detected
by immunoblot analysis by using a polyclonal CPP-32 antibody (a gift
from P. R. Sekaly).
|
|
Caspase 8 and caspase 9 are involved in IRF-3-dependent activation
of CPP-32/caspase 3.
We next examined which apoptotic pathways led
to caspase 3 activation in Sendai virus-infected or
IRF-3(5D)-overexpressing cells. Several studies have reported that at
least two caspases (caspases 8 and 9) can activate CPP-32/caspase 3 following death receptor ligation or exposure to cytotoxic agents
(8, 15, 24, 31, 43). To verify if these caspases are
involved in Sendai virus- and IRF-3(5D)-induced apoptosis, highly
specific inhibitors of the caspases were used in a pharmacological
approach, and the effects of these inhibitors in IRF-3-expressing
Jurkat cells are shown in Fig. 8A. The
use of a broad-spectrum caspase inhibitor, z-VAD, completely abrogated
anti-Fas antibody (APO-1-3)- and etoposide-induced apoptosis in
rtTA-Jurkat IRF-3(5D). Under the same conditions, z-IETD
which is
selective for caspase 8
inhibited the effect of anti-Fas antibody
which stimulates FADD-dependent cell death though caspase 8 activation,
but had no effect on etoposide-induced apoptosis. In contrast, the
caspase 9 specific inhibitor z-LEHD blocked the apoptotic effect of
etoposide which bypasses caspase 8 and induces apoptosis by triggering
cytochrome c release and caspase 9 activation.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 8.
Caspase 8 and caspase 9 are involved in IRF-3-dependent
activation of CPP-32/caspase-3. (A) rtTA-Jurkat IRF-3(5D) cells were
cultured in the presence of 4 µg of APO-1-3 per ml or 50 µM
Etoposide for 48 h in the continuous presence of caspase blockers
zVAD, zIETH, and zLEHD (200 µM), as indicated. Viability was
evaluated by using trypan blue exclusion. (B) wtIRF-3-expressing Jurkat
cells were treated for 48 h with DOX (5 µg/ml) to stimulate
IRF-3 production and were then infected with Sendai virus (400 HAU/ml/106 cells) for 24, 48, or 72 h in the
continuous presence of caspase blockers zVAD, zIETH, and zLEHD (200 µM). Viability was evaluated by using trypan blue exclusion. (C)
IRF-3(5D)-expressing Jurkat cells were treated with DOX (5 µg/ml) for
24, 48, or 72 h to stimulate IRF-3(5D) production. DOX treatment
was accomplished in the continuous presence of caspase blockers zVAD,
zIETH, and zLEHD (200 µM). Viability was evaluated by using trypan
blue exclusion. Symbols in B and C: , Sendai virus; , Sendai
virus plus zLEHD; , Sendai virus plus zIETD; , Sendai virus plus
zVAD. (D) IRF-3(5D)-expressing Jurkat cells were treated with DOX (5 µg/ml) for 24, 48, and 72 h; whole-cell extracts were prepared
at different times after treatment with DOX and were incubated with
fluorogenic substrates for caspase 8 ( ) and caspase 9 ( ) as
described in Materials and Methods. Caspase activity is represented by
the fluorescence ratio between DOX-induced versus noninduced cells.
|
|
By using a similar approach, we next verified the pathway by which
Sendai virus and IRF-3(5D) induce apoptosis. In Fig. 8B, treatment of
wtIRF-3 Jurkat cells with the caspase inhibitor z-IETD abrogated almost
70% of the apoptotic response observed at 72 h after Sendai virus
infection. The use of z-LEHD partially impaired Sendai virus-induced
cell death, suggesting that caspase 9 may also be involved in the
pathway leading to apoptosis. These caspase inhibitors produced similar
apoptotic inhibitor effects in IRF-3(5D)-expressing cells (Fig. 8C).
These data illustrate the high potency and selectivity of these
apoptosis inhibitors and, more importantly, demonstrate that caspase 8 and to a lesser extent caspase 9 are involved in IRF-3(5D)- and Sendai
virus-induced apoptosis.
To demonstrate that IRF-3(5D) is sufficient to induce the activation of
caspases 8 and 9, lysates from DOX-induced rtTA-Jurkat IRF-3(5D)-expressing cells were used in combination with fluorogenic substrates for both caspases to quantify their respective activities. As shown in Fig. 8D, the activity of both caspases was significantly increased 48 to 72 h after DOX induction, a time interval that corresponds with the activation of CPP-32/caspase 3 (Fig. 7B). Similar
results were also obtained when cleavage of proapoptotic caspase 8 was
monitored by immunoblot analysis (data not shown). Caspase 9 was not as
strongly activated as caspase 8; however, as shown in Fig. 8B and C,
IRF-3(5D) induction of apoptosis may involve multiple pathways,
concomitantly requiring both caspase 8 and 9.
 |
DISCUSSION |
In this study, the potential growth modulatory properties of the
IRF-3 transcription factor were analyzed in cell lines constitutively or inducibly expressing IRF-3 transgenes. The constitutively active form of IRF-3 [IRF-3(5D)] was shown to induce apoptosis in human embryonic kidney 293 and Jurkat T cells, while wtIRF-3 had no effect on
its own. Viral infection of cells overexpressing wtIRF-3 enhanced the
number of cells undergoing apoptosis by two to threefold, depending on
the cell type, while a dominant negative form of IRF-3 (IRF-3
N)
interfered with virus-induced apoptosis in 293 cells, thus
demonstrating that IRF-3 activation may initiate apoptotic signalling.
The ability of IRF-3 to signal apoptosis is likely limited to
virus-infected cells, since virus infection is the only mechanism known
to activate IRF-3 (21); furthermore, dominant negative IRF-3
did not inhibit apoptosis induced by osmotic stress (data not shown).
Activation of caspase 8, and to a lesser extent caspase 9 and
CPP-32/caspase 3, were involved in both Sendai virus- and
IRF-3(5D)-induced apoptosis. However, it is not clear whether IRF-3 is
able to independently regulate both the mitochondrial apoptotic pathway
as well as the death-induced signaling complex (DISC) that comprises
caspase 8. These effects may depend on the cell type. For example, in
type II cells, including Jurkat cells, it has been reported that
caspase 8 and caspase 3 are activated downstream of the mitochondria
(40). In contrast, in type I cells, apoptosis is relatively
mitochondrion independent, and caspase 8 is rapidly activated at the
DISC prior to caspase 3 activation (40). However, inhibition
of caspase 8, rather than mitochondrion-related caspase 9, in
IRF-3(5D)-expressing cells profoundly repressed apoptosis. It is
plausible that IRF-3 may induce an unknown gene(s) that contributes to
apoptosis by regulating the DISC to convert Jurkat cells into type I
cells. Therefore, inhibiting caspase 9 would not dramatically affect
IRF-3-mediated apoptosis, as described in this study. Nevertheless,
some caspase 9 activity was observed and may be explained by recent
data demonstrating that activated caspase 8 can recruit mitochondrial
input into the caspase-9-mediated activation of caspase 3 via cleavage
of Bid-2 (28). It remains to be determined what proapoptotic
genes may be induced by IRF-3; interestingly, recent studies using DNA array technology revealed that IFN induces a number of proteins known
to be involved in the regulation of apoptosis that were not previously
considered to harbor ISREs in their promoter regions (14).
In uninfected cells, IRF-3 resides in the cytoplasm in a closed
conformation that maintains it in a latent inactive state (21,
27). Hence, overexpression of wtIRF-3 per se does not induce
transcriptional up regulation of target genes. Virus-induced phosphorylation of IRF-3 leads to a conformational change that relieves
autoinhibition and permits its dimerization and translocation to the
nucleus and transcriptional activation of target genes. The
constitutively active form of IRF-3
IRF-3(5D)
does not require this
posttranslational modification; it is able to dimerize, interact with
the CBP/p300 coactivator, and localize to the nucleus where it is a
potent transactivator (21, 26, 27). These results are
consistent with the observation that wtIRF-3 overexpression alone does
not induce apoptosis without activation by virus infection, whereas
IRF-3(5D) is sufficient to induce apoptosis.
Other members of the IRF family of transcription factors have been
implicated in growth control and apoptosis. IRF-1 functions as a tumor
suppressor, while overexpression of IRF-2 results in cell
transformation of NIH 3T3 cells and tumor formation in nude mice
(17, 34). IRF-1 mediates oncogene- and DNA damage-induced apoptosis by transcriptionally activating target genes such as caspase
1 and by cooperating with p53 to induce p21/WAF expression (36,
45, 46). Chromosomal deletion at the IRF-1 locus has been
associated with leukemia and preleukemic myelodysplasia, further
highlighting the important functions of IRF proteins in growth control
(55). Although IRF-1 is activated upon viral infection,
Tanaka et al. using IRF-1 knockout cells demonstrated that IRF-1 is not
necessary for virus-induced apoptosis (47). This study
further demonstrated that alpha/beta IFN was essential for
virus-induced apoptosis and neutralization of IFN reduced viral induced
death. Furthermore, IFNAR and Stat1
/
cells, were also
deficient for virus-induced apoptosis (47). It is possible
that IRF-3 may subvert the function of IRF-1 since both proteins bind
to the same DNA sequence element (GAAANNGAAANN); alternatively, IRF-3 may in some circumstances induce IRF-1
expression through the ISRE in the IRF-1 promoter. In our experiments,
both Sendai virus- and IRF-3(5D)-induced apoptosis were not diminished by the use of antibody capable of neutralizing alpha/beta IFNs. Furthermore, RNase protection analysis showed that in 293 and Jurkat
cells, overexpression of IRF-3(5D) alone was not sufficient to induce
mRNA production for either IFN-
or IFN-
. These results imply that
IFN secretion is not essential for Sendai virus or IRF-3 activation of
apoptosis, but rather indicate that several mechanisms of virus-induced
apoptosis may exist. This hypothesis is supported by the observation
that Sendai virus can induce apoptosis through the activation of
FLICE/caspase 8 and CPP-32/caspase 3 by a mechanism independent of
tumor necrosis factor and Fas receptor ligand binding (8,
9).
Our study further clarifies the molecular pathway used by
paramyxoviruses to induce apoptosis. Notably, the fact that IRF-3(5D) overexpression per se is sufficient for caspase 8 and caspase 9 activation and induction of apoptosis implies that phosphorylation of
IRF-3 and subsequent nuclear translocation of IRF-3 is part of the
general pathway involved in the regulation of cell death by
paramyxoviruses. It is not possible to rule out the parallel activation
of other apoptotic pathways since overexpression of a dominant negative
mutant of IRF-3 (IRF-3
N) decreased Sendai virus-induced apoptosis
by 50% but did not completely block virus-induced apoptosis (Fig. 5).
Likewise, it is not possible to rule out the synthesis of a low level
of endogenous IFN that may escape detection but nonetheless contribute
to IRF-3-mediated apoptosis (8). The recent observation that
the dsRNA protein kinase PKR regulates apoptosis through the
involvement of the death receptors represents another pathway used by
viruses to induce apoptosis in target cells (7).
A role for IRF-3 in mediating virus-induced apoptosis is supported by
studies with the human papilloma virus E6 protein. E6, which induces
cellular transformation via p53-dependent and independent mechanisms,
was found to interact with IRF-3 and block its transactivation potential (38). Since p53 gene deletion cannot account for
the impaired differentiation seen in E6-expressing transgenic mice, E6
may induce oncogenesis by modulating IRF-3-regulated cell proliferation or apoptosis (38). Our group and others have also
demonstrated that virus infection leads to NF-
B activation in target
cells (2, 13, 16). Furthermore, it is well established that
NF-
B provides a protective antiapoptotic function in most cell types (12) and therefore could act as a physiological antagonist
of IRF-3 with regard to the induction of apoptosis. In support of this
contention, the apoptotic effect of IRF-3 is partially masked by
NF-
B activation, since expression of a super repressor form of I
B
(2N
4) (23) increased Sendai virus-induced apoptosis by
70% in 293 cells (data not shown).
Activation of the IRF-3 transcription factor by viral infection may
thus serve several functions. A role for IRF-3 in immediate-early activation of immunomodulatory RANTES and IFN gene expression has
recently been demonstrated (21, 25). These proteins are necessary for the host to mount an effective immune response. Our
results illustrate that IRF-3 plays an additional role in mediating
Sendai virus-induced apoptosis. Effective viral containment requires
that infected cells are quickly eliminated. IRF-3 is an attractive
candidate for mediating virus-induced apoptosis since IRF-3 is only
activated upon viral infection and its activation
as demonstrated by
transfection studies with IRF-3(5D)
induces up to a 200-fold increase
in the transcriptional activity of responsive genes (25,
26). Activation of IRF-3 would therefore allow an immediate-early
response to virus infection that involves both the stimulation of the
antiviral response and the elimination of virus-infected cells by apoptosis.
 |
ACKNOWLEDGMENTS |
We thank Pierre Rafick Sékaly, Illka Julkunen, and Paula
Pitha-Rowe for providing reagents used in this study.
This research was supported by operating grants from the Medical
Research Council of Canada (MRC) (J.H.) and the National Institutes of
Health (G.B.). C.H. was supported by an MRC studentship, M.J.S. was
supported by an MRC postdoctoral Fellowship, C.D. was supported by a
McGill Major studentship, R.L. was supported by a Fraser Monat
McPherson Fellowship from McGill University, and J.H. was supported by
an MRC Senior Scientist award.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Lady Davis
Institute for Medical Research, 3755 Cote Ste. Catherine, Montreal,
Quebec, Canada H3T1E2. Phone: (514) 340-8222, ext. 5265. Fax: (514)
340-7576. E-mail: mijh{at}musica.mcgill.ca.
 |
REFERENCES |
| 1.
|
Adams, J. M., and S. Cory.
1998.
The Bcl-2 protein family: arbiters of cell survival.
Science
281:1322-1326[Abstract/Free Full Text].
|
| 2.
|
Algarte, M.,
H. Kwon,
P. Genin, and J. Hiscott.
1999.
Identification by in vivo genomic footprinting of a transcriptional switch containing NF- B and Sp1 that regulates the I B promoter.
Mol. Cell Biol.
19:6140-6153[Abstract/Free Full Text].
|
| 3.
|
Ashkenazi, A., and V. M. Dixit.
1998.
Death receptors: signaling and modulation.
Science
281:1305-1308[Abstract/Free Full Text].
|
| 4.
|
Au, W.-C.,
P. A. Moore,
W. Lowther,
Y.-T. Juang, and P. M. Pitha.
1995.
Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes.
Proc. Natl. Acad. Sci. USA
92:11657-11661[Abstract/Free Full Text].
|
| 5.
|
Au, W.-C.,
P. A. Moore,
D. W. LaFleur,
B. Tombal, and P. M. Pitha.
1998.
Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes.
J. Biol. Chem.
273:29210-29217[Abstract/Free Full Text].
|
| 6.
|
Baichwal, V. R., and P. A. Baeuerle.
1997.
Apoptosis: activate NF- B or die?
Curr. Biol.
7:R94-R96[CrossRef][Medline].
|
| 7.
|
Balachandran, S.,
C. N. Kim,
W. C. Yeh,
T. W. Mak,
K. Bhalla, and G. N. Barber.
1998.
Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling.
EMBO J.
17:6888-6902[CrossRef][Medline].
|
| 8.
|
Balachandran, S.,
C. Roberts,
T. Kipperman,
K. Bhalla,
R. Compans,
D. Archer, and G. Barber.
2000.
Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway.
J. Virol.
74:1513-1523[Abstract/Free Full Text].
|
| 9.
|
Bitzer, M.,
F. Prinz,
M. Bauer,
M. Spiegel,
W. J. Neubert,
M. Gregor,
K. Schulze-Osthoff, and U. Lauer.
1999.
Sendai virus infection induces apoptosis through activation of caspase-8 (FLICE) and caspase-3 (CPP32).
J. Virol.
73:702-708[Abstract/Free Full Text].
|
| 10.
|
Bump, N. J.,
M. Hackett,
M. Hagunin,
S. Seshagiri,
K. Brady,
P. Chen,
C. Ferenz,
S. Franklin,
T. Ghayur,
P. Li,
P. Lican,
J. Mankovich,
L. Shi,
A. H. Greenberg,
L. K. Miller, and W. W. Wong.
1995.
Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35.
Science
269:1885-1888[Abstract/Free Full Text].
|
| 11.
|
Cryns, V., and J. Yuan.
1998.
Proteases to die for.
Genes Dev.
12:1551-1570[Free Full Text].
|
| 12.
|
DeLuca, C.,
H. Kwon,
R. Lin,
M. Wainberg, and J. Hiscott.
1999.
NF- B activation and HIV-1 induced apoptosis.
Cytokine Growth Factor Rev.
10:235-253[CrossRef][Medline].
|
| 13.
|
DeLuca, C.,
L. Petropoulos,
D. Zmeureanu, and J. Hiscott.
1999.
Nuclear I B maintains persistent NF- B activation in HIV-1-infected myeloid cells.
J. Biol. Chem.
274:13010-13016[Abstract/Free Full Text].
|
| 14.
|
Der, S. D.,
A. Zhou,
B. R. G. Williams, and R. H. Silverman.
1998.
Identification of genes differentially regulated by interferon , , or using oligonucleotide arrays.
Proc. Natl. Acad. Sci. USA
95:15623-15628[Abstract/Free Full Text].
|
| 15.
|
Faleiro, L.,
R. Kobayashi,
H. Fearnhead, and Y. Lazebnik.
1997.
Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells.
EMBO J.
16:2271-2281[CrossRef][Medline].
|
| 16.
|
Garoufalis, E.,
I. Kwan,
R. Lin,
A. Mustafa,
N. Pepin,
A. Roulston,
J. Lacoste, and J. Hiscott.
1994.
Viral induction of the human interferon beta promoter: modulation of transcription by NF- B/rel proteins and interferon regulatory factors.
J. Virol.
68:4707-4715[Abstract/Free Full Text].
|
| 17.
|
Harada, H.,
M. Kitagawa,
N. Tanaka,
H. Yamamoto,
K. Harada,
M. Ishihara, and T. Taniguchi.
1993.
Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2.
Science
259:971-974[Abstract].
|
| 18.
|
Henderson, S.,
D. Huen,
M. Rowe,
C. Dawson,
G. Johnson, and A. Rickinson.
1993.
Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death.
Proc. Natl. Acad. Sci. USA
15:8479-8483.
|
| 19.
|
Henderson, S.,
M. Rowe,
C. Gregory,
D. Croom-Carter,
F. Wang,
R. Longnecker,
E. Kieff, and A. Rickinson.
1991.
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein-1 protects infected B-cells from programmed cell death.
Cell
65:1107-1115[CrossRef][Medline].
|
| 20.
|
Hiscott, J.,
H. Nguyen, and R. Lin.
1995.
Molecular mechanisms of interferon beta gene induction.
Semin. Virol.
6:161-173.
|
| 21.
|
Hiscott, J.,
P. Pitha,
P. Génin,
H. Nguyen,
C. Heylbroeck,
Y. Mamane,
M. Algarté, and R. Lin.
1999.
Triggering the interferon response: the role of IRF-3 transcription factor.
J. Interferon Cytokine Res.
19:1-13[CrossRef][Medline].
|
| 22.
|
Jacobson, M. D.,
M. Weil, and M. C. Raff.
1997.
Programmed cell death in animal development.
Cell
88:347-354[CrossRef][Medline].
|
| 23.
|
Kwon, H.,
N. Pelletier,
C. DeLuca,
P. Genin,
S. Cisternas,
R. Lin,
M. A. Wainberg, and J. Hiscott.
1998.
Inducible expression of I B repressor mutants interferes with NF- B activity and HIV-1 replication in Jurkat T cells.
J. Biol. Chem.
273:7431-7440[Abstract/Free Full Text].
|
| 24.
|
Li, P.,
D. Nijhawan,
I. Budihardjo,
S. M. Srinivasula,
M. Ahmad,
E. S. Alnemri, and X. Wang.
1997.
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade.
Cell
91:479-489[CrossRef][Medline].
|
| 25.
|
Lin, R.,
C. Heylbroeck,
P. Genin,
P. Pitha, and J. Hiscott.
1999.
Essential role of IRF-3 in direct activation of RANTES gene transcription.
Mol. Cell Biol.
19:959-966[Abstract/Free Full Text].
|
| 26.
|
Lin, R.,
C. Heylbroeck,
P. M. Pitha, and J. Hiscott.
1998.
Virus dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential and proteasome mediated degradation.
Mol. Cell Biol.
18:2986-2996[Abstract/Free Full Text].
|
| 27.
|
Lin, R.,
Y. Mamane, and J. Hiscott.
1999.
Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains.
Mol. Cell. Biol.
19:2465-2474[Abstract/Free Full Text].
|
| 28.
|
Luo, X.,
I. Budihardjo,
H. Zou,
C. Slaughter, and X. Wang.
1998.
Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.
Cell
94:481-490[CrossRef][Medline].
|
| 29.
|
Marie, I.,
J. E. Durbin, and D. E. Levy.
1998.
Differential viral induction of distinct interferon- genes by positive feedback through interferon regulatory factor-7.
EMBO J.
17:6660-6669[CrossRef][Medline].
|
| 30.
|
Miura, M.,
H. Zhu,
R. Rotello,
E. A. Hartwieg, and J. Yuan.
1993.
Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3.
Cell
19:653-660.
|
| 31.
|
Muzio, M.,
G. S. Salvesen, and V. M. Dixit.
1997.
FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens.
J. Biol. Chem.
272:2952-2956[Abstract/Free Full Text].
|
| 32.
|
Nguyen, H.,
J. Hiscott, and P. M. Pitha.
1997.
The growing family of IRF transcription factors.
Cytokine Growth Factor Rev.
8:293-312[CrossRef][Medline].
|
| 33.
|
Nguyen, H.,
R. Lin, and J. Hiscott.
1997.
Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins.
Oncogene
15:1425-1435[CrossRef][Medline].
|
| 34.
|
Nguyen, H.,
A. Mustafa,
J. Hiscott, and R. Lin.
1995.
Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain.
Oncogene
11:537-544[Medline].
|
| 35.
|
Nicholson, D. W.,
A. Ali,
N. A. Thornberry,
J. P. Vaillancourt,
C. K. Ding,
M. Gallant,
Y. Gareau,
P. R. Griffin,
M. Labelle,
Y. A. Lazebnik,
N. A. Munday,
S. M. Raju,
M. E. Smulson,
T.-T. Yamin,
V. L. Yu, and D. K. Miller.
1995.
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis.
Nature
376:37-43[CrossRef][Medline].
|
| 36.
|
Ozawa, H.,
T. Matsuyama,
T. W. Mak,
S. Aizawa,
T. Tokino,
M. Oren, and T. Taniguchi.
1996.
Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage.
Nature
382:816-818[CrossRef][Medline].
|
| 37.
|
Parekh, B. S., and T. Maniatis.
1999.
Virus infection leads to localized hyperacetylation of histones H3 and H4 at the IFN- promoter.
Mol. Cell
3:125-129[CrossRef][Medline].
|
| 38.
|
Ronco, L.,
A. Karpova,
M. Vidal, and P. Howley.
1998.
Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity.
Genes Dev.
12:2061-2072[Abstract/Free Full Text].
|
| 39.
|
Sato, M.,
N. Hata,
M. Asagiri,
T. Nakaya,
T. Taniguchi, and N. Tanaka.
1998.
Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7.
FEBS Lett.
441:106-110[CrossRef][Medline].
|
| 40.
|
Scaffidi, C.,
S. Fulda,
A. Srinivasan,
C. Friesen,
F. Li,
K. Tomaselli,
K. Debatin,
P. Krammer, and M. Peter.
1998.
Two CD95 (APO-1/Fas) signaling pathways.
EMBO J.
17:1675-1687[CrossRef][Medline].
|
| 41.
|
Schulze-Osthoff, K.,
D. Ferrari,
M. Los,
S. Wesselborg, and M. E. Peter.
1998.
Apoptosis signaling by death receptors.
Eur. J. Biochem.
254:439-459[Medline].
|
| 42.
|
Shen, Y., and T. E. Shenk.
1995.
Viruses and apoptosis.
Curr. Opin. Gen. Dev.
5:105-111[CrossRef][Medline].
|
| 43.
|
Srinivasula, S. M.,
M. Ahmad,
T. Fernandes-Alnemri,
G. Litwack, and E. S. Alnemri.
1996.
Molecular ordering of the Fas-apoptotic pathway: the Fas/Apo-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple ced-3/ICE-like cysteine proteases.
Proc. Natl. Acad. Sci. USA
93:14486-14491[Abstract/Free Full Text].
|
| 44.
|
Sylla, B. S.,
S. C. Hung,
D. M. Davidson,
E. Hatzivassiliou,
N. L. Malinin,
D. Wallach,
T. Gilmore,
E. Kieff, and G. Mosialos.
1998.
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF- B through a pathway that includes the NF- B-inducing kinase and the I B kinases IKK and IKK .
Proc. Natl. Acad. Sci. USA
95:10106-10111[Abstract/Free Full Text].
|
| 45.
|
Tamura, T.,
M. Ishihara,
M. S. Lamphier,
N. Tanaka,
I. Oishi,
S. Aizawa,
T. Matsuyama,
T. W. Mak,
S. Taki, and T. Taniguchi.
1995.
An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T-lymphocytes.
Nature
376:596-599[CrossRef][Medline].
|
| 46.
|
Tanaka, N.,
M. Ishihara,
M. Kitagawa,
H. Harada,
T. Kimura,
T. Matsuyama,
M. S. Lamphier,
S. Aizawa,
T. W. Mak, and T. Taniguchi.
1994.
Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1.
Cell
77:829-839[CrossRef][Medline].
|
| 47.
|
Tanaka, N.,
M. Sato,
M. S. Lamphier,
H. Nozawa,
E. Oda,
S. Noguchi,
R. D. Schreiber,
Y. Tsujimoto, and T. Taniguchi.
1998.
Type I interferons are essential mediators of apoptotic death in virally infected cells.
Genes Cells
3:29-37[Abstract].
|
| 48.
|
Teodoro, J. G., and P. E. Branton.
1997.
Regulation of apoptosis by viral gene products.
J. Virol.
71:1739-1746[Medline].
|
| 49.
|
Thome, M.,
P. Schneider,
K. Hofmann,
H. Kickenscher,
E. Meinl,
F. Neipel,
C. Mattmann,
K. Burns,
J.-L. Bodmer,
M. Schröter,
C. Scaffidi,
P. H. Krammer,
M. E. Peter, and J. Tschopp.
1997.
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.
Nature
386:517-521[CrossRef][Medline].
|
| 50.
|
Thornberry, N. A., and Y. Lazebnik.
1998.
Caspases: enemies within.
Science
281:1312-1316[Abstract/Free Full Text].
|
| 51.
|
Vaux, D. L., and A. Strasser.
1996.
The molecular biology of apoptosis.
Proc. Natl. Acad. Sci. USA
93:2239-2244[Abstract/Free Full Text].
|
| 52.
|
Vilcek, J., and G. Sen.
1996.
Interferons and other cytokines, p. 375-399.
In
B. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Lippincott-Raven, Philadelphia, Pa.
|
| 53.
|
Wathelet, M. G.,
C. H. Lin,
B. S. Parakh,
L. V. Ronco,
P. M. Howley, and T. Maniatis.
1998.
Virus infection induces the assembly of coordinately activated transcription factors on the IFN- enhancer in vivo.
Mol. Cell
1:507-518[CrossRef][Medline].
|
| 54.
|
Weaver, B. K.,
K. P. Kumar, and N. C. Reich.
1998.
Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1.
Mol. Cell Biol.
18:1359-1368[Abstract/Free Full Text].
|
| 55.
|
Willman, C. L.,
C. E. Sever,
M. G. Pallavicini,
H. Harada,
N. Tanaka,
M. L. Slovak,
H. Yamamoto,
K. Harada,
T. C. Meeker,
A. F. List, and T. Taniguchi.
1993.
Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasias.
Science
259:968-971[Abstract].
|
| 56.
|
Yoneyama, M.,
W. Suhara,
Y. Fukuhara,
M. Fukada,
E. Nishida, and T. Fujita.
1998.
Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300.
EMBO J.
17:1087-1095[CrossRef][Medline].
|
Journal of Virology, April 2000, p. 3781-3792, Vol. 74, No. 8
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bartlett, E. J., Cruz, A.-M., Esker, J., Castano, A., Schomacker, H., Surman, S. R., Hennessey, M., Boonyaratanakornkit, J., Pickles, R. J., Collins, P. L., Murphy, B. R., Schmidt, A. C.
(2008). Human Parainfluenza Virus Type 1 C Proteins Are Nonessential Proteins That Inhibit the Host Interferon and Apoptotic Responses and Are Required for Efficient Replication in Nonhuman Primates. J. Virol.
82: 8965-8977
[Abstract]
[Full Text]
-
Li, Q., Tang, L., Roberts, P. C., Kraniak, J. M., Fridman, A. L., Kulaeva, O. I., Tehrani, O. S., Tainsky, M. A.
(2008). Interferon Regulatory Factors IRF5 and IRF7 Inhibit Growth and Induce Senescence in Immortal Li-Fraumeni Fibroblasts. Mol Cancer Res
6: 770-784
[Abstract]
[Full Text]
-
Dogusan, Z., Garcia, M., Flamez, D., Alexopoulou, L., Goldman, M., Gysemans, C., Mathieu, C., Libert, C., Eizirik, D. L., Rasschaert, J.
(2008). Double-Stranded RNA Induces Pancreatic {beta}-Cell Apoptosis by Activation of the Toll-Like Receptor 3 and Interferon Regulatory Factor 3 Pathways. Diabetes
57: 1236-1245
[Abstract]
[Full Text]
-
Clement, J.-F., Bibeau-Poirier, A., Gravel, S.-P., Grandvaux, N., Bonneil, E., Thibault, P., Meloche, S., Servant, M. J.
(2008). Phosphorylation of IRF-3 on Ser 339 Generates a Hyperactive Form of IRF-3 through Regulation of Dimerization and CBP Association. J. Virol.
82: 3984-3996
[Abstract]
[Full Text]
-
Peters, K., Chattopadhyay, S., Sen, G. C.
(2008). IRF-3 Activation by Sendai Virus Infection Is Required for Cellular Apoptosis and Avoidance of Persistence. J. Virol.
82: 3500-3508
[Abstract]
[Full Text]
-
Nishimura, K., Segawa, H., Goto, T., Morishita, M., Masago, A., Takahashi, H., Ohmiya, Y., Sakaguchi, T., Asada, M., Imamura, T., Shimotono, K., Takayama, K., Yoshida, T., Nakanishi, M.
(2007). Persistent and Stable Gene Expression by a Cytoplasmic RNA Replicon Based on a Noncytopathic Variant Sendai Virus. J. Biol. Chem.
282: 27383-27391
[Abstract]
[Full Text]
-
Holm, G. H., Zurney, J., Tumilasci, V., Leveille, S., Danthi, P., Hiscott, J., Sherry, B., Dermody, T. S.
(2007). Retinoic Acid-inducible Gene-I and Interferon-beta Promoter Stimulator-1 Augment Proapoptotic Responses Following Mammalian Reovirus Infection via Interferon Regulatory Factor-3. J. Biol. Chem.
282: 21953-21961
[Abstract]
[Full Text]
-
Romieu-Mourez, R., Solis, M., Nardin, A., Goubau, D., Baron-Bodo, V., Lin, R., Massie, B., Salcedo, M., Hiscott, J.
(2006). Distinct Roles for IFN Regulatory Factor (IRF)-3 and IRF-7 in the Activation of Antitumor Properties of Human Macrophages. Cancer Res.
66: 10576-10585
[Abstract]
[Full Text]
-
Bibeau-Poirier, A., Gravel, S.-P., Clement, J.-F., Rolland, S., Rodier, G., Coulombe, P., Hiscott, J., Grandvaux, N., Meloche, S., Servant, M. J.
(2006). Involvement of the I{kappa}B Kinase (IKK)-Related Kinases Tank-Binding Kinase 1/IKKi and Cullin-Based Ubiquitin Ligases in IFN Regulatory Factor-3 Degradation. J. Immunol.
177: 5059-5067
[Abstract]
[Full Text]
-
Guerra, S., Lopez-Fernandez, L. A., Garcia, M. A., Zaballos, A., Esteban, M.
(2006). Human Gene Profiling in Response to the Active Protein Kinase, Interferon-induced Serine/threonine Protein Kinase (PKR), in Infected